
As an Amazon Associate and affiliate partner, Menrva Books earns from qualifying purchases. Learn more
Parkinson’s disease is the most common movement disorder affecting 1% of people older than 60 years. Rivastigmine is a pseudo-irreversible, carbamate type-brain selective, dual Ache-BuChE inhibitor is used for mild to moderate PD and it has less side effects compared to levodopa. For developing a ligand based analogue for Rivastigmine, CADD and GOLD docking is used. In this work, the binding modes of the putative/proposed inhibitors were obtained by carefully aligning them with the known crystal structures of inhibitors in the active site of the 1GQR. These inhibitors, which are shown in the above Figures, were then evaluated by performing minimization calculations both in solvent and in complex using the MM+ force field. The technical details used for estimating relative binding affinities using energy components obtained from minimizations of each inhibitor, both in solvent as well as in complex phases, were explained by four stage protocol as described in the in-methodology section. A comparison of the relative binding affinities for structurally similar Inhibitors to Rivastigmine indicates that the molecular mechanics methods gave suitable analogues. These results clearly indicate that before synthesis and biochemical testing of new analogues, one can use molecular mechanics-based methods for qualitative assessment of relative binding affinities for speeding up drug discovery process by eliminating less potent compounds from synthesis. The inhibitor with the substituent R=CCl3 (-63.608208) is identified as the most suitable analogues in the present study need to be further evaluated in laboratory.
This study investigates the development of novel inhibitors for acetylcholinesterase to combat Parkinson's disease using computational methods. The research focuses on designing ligands analogous to Rivastigmine, a known dual acetylcholinesterase and butyrylcholinesterase inhibitor used for Parkinson's disease treatment. By employing CADD and GOLD docking techniques, the study analyzes the binding modes of proposed inhibitors within the active site of the 1GQR enzyme, comparing them against crystal structures of known inhibitors. The methodology involves minimization calculations and a four-stage protocol to estimate relative binding affinities, aiming to accelerate the drug discovery process by identifying potent compounds computationally before laboratory synthesis and testing.
The research presents a computational approach to identifying potential drug candidates for Parkinson's disease by focusing on acetylcholinesterase inhibition. The methodology described, involving CADD, docking, and molecular mechanics calculations, is a standard practice in pharmaceutical research for initial screening. The study's conclusion highlights the utility of these computational methods for qualitative assessment of binding affinities, thereby streamlining the drug discovery pipeline. The identification of a specific inhibitor analogue (R=CCl3) as most promising suggests a focused outcome from the computational analysis.
Page Count:
74
Publication Date:
2021-07-19
Publisher:
Independently published
ISBN-13:
9798539695255
No comments yet. Be the first to share your thoughts!